Bodai, Zsolt
Bishop, Alena L.
Gantz, Valentino M. http://orcid.org/0000-0003-2453-0711
Komor, Alexis C. http://orcid.org/0000-0001-5043-0998
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DP5OD023098)
National Science Foundation (MCB-2048207)
Article History
Received: 17 September 2021
Accepted: 7 April 2022
First Online: 9 May 2022
Competing interests
: A.C.K. is a member of the SAB of Pairwise Plants, is an equity holder for Pairwise Plants and Beam Therapeutics, and receives royalties from Pairwise Plants, Beam Therapeutics, and Editas Medicine via patents licensed from Harvard University. A.C.K.’s interests have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. V.M.G. is a founder of and has equity interests in Synbal, Inc. and Agragene, Inc., companies that may potentially benefit from the research results described in this manuscript. V.M.G. also serves on both the company’s Scientific Advisory Board and the Board of Directors of Synbal, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. All authors are listed as inventors in a Regents of the University of California pending patent application (US63/243,260) on the use of secondary gRNAs to improve precision genome editing.